ConvaTec : MSA Statement_FY22

Modern Slavery Act Statement

Convatec Group Plc

18 May 2023

Background

Modern slavery is defined as the recruitment, movement, harbouring or receiving of children, women or men through the use of force, coercion, abuse of vulnerability, deception or other means for the purpose of exploitation. Incidents of modern slavery can occur in any sector, industry, and geographic region.

Convatec has zero tolerance for any form of modern slavery in our operations and supply chain.

With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring - a promise we extend to all our stakeholders. Our vision of pioneering trusted medical solutions to improve the lives we touch, refers not only to the lives of those who use our products, but also the lives of our colleagues and all those involved in our supply chain.

Section 54 of the UK Modern Slavery Act 2015 requires that each organisation within the United Kingdom which has an annual turnover in excess of £36 million produces an annual public statement, approved by the board of directors, detailing the steps it has taken to prevent slavery and human trafficking in its local and global operations and full value chain. At Convatec, we take this as an opportunity to reflect on the ways in which we execute our core value of 'Doing what's right' and how that impacts our people, culture, other stakeholders and business.

We are committed to preventing slavery and human trafficking, and so we implement policies and processes to prevent, assess, detect and report violations within our own operations, which by extension includes how we support customers, as well as through our supply chains. This statement, which is published in accordance with section 54 (1) of the Modern Slavery Act 2015, outlines our approach and activities during the period 1 January 2022 to 31 December 2022.

Our approach

'Do what's right' and 'Own it' are two of our core values that represent who we are at Convatec. We recognise that we need to make sure that our business decisions at all levels embody these values and that we embed ethical behaviour in everything we do. By doing so, we earn trust, build stakeholder confidence and ensure that, at all times, we act with integrity and do what we say we will do. This is essential if we are to achieve our vision and create value for our stakeholders.

All colleagues are involved in ensuring that modern slavery is not tolerated. To ensure that awareness around detecting and preventing modern slavery remains high, Convatec maintains a cross-functional Human Rights Committee that keeps our structures and processes current to global dynamics.

To prevent modern slavery in our business and supply chain, we must consider our:

• Organisational structure and supply chain
• Human rights-related policies
• Due diligence processes in relation to slavery and human trafficking
• Risk assessment and management structures
• Response to identified issues
• Training on modern slavery and trafficking

This statement details our activities and approach in each of these areas.

Our organisational structure

Convatec develops and produces innovative medical solutions that give people living with certain chronic conditions improved confidence, freedom and mobility. Focused on the chronic care market, we offer a range of services to support these people and the healthcare professionals who

1

care for them. We market and sell our solutions and services in four categories: advanced wound care, ostomy care, continence and critical care1 and infusion care.

We market and sell our products and services in around 100 countries and at December 2022, owned and operated nine1 manufacturing facilities located in seven countries: the UK, Denmark, the United States, Slovakia, Netherlands2 , the Dominican Republic and Mexico. Our reported revenue for 2022 was $2,073m, split geographically as follows: Europe ($689m - 33%), North America ($1,090m - 53%), and Rest of world ($294m - 14%). Our Group structure includes over 50 active companies. This statement is relevant to all our active companies, including the following three active companies located in the UK: Convatec Group Plc, Convatec Limited and Amcare Limited.

As noted above, we market and sell our products and services in four categories. We have a direct presence in certain markets and an extensive network of wholesalers and distributors in other markets.

• Advanced Wound Care (2022 revenue: $621m - 30.0%): advanced wound dressings for the management of chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.
• Ostomy Care (2022 revenue: $522m - 25%): devices, accessories and services for people with a stoma (a surgically-created opening where bodily waste is discharged), commonly resulting from causes such as colorectal cancer, inflammatory bowel disease and bladder cancer.
• Continence & Critical Care1 (2022 revenue: $546m - 26%): products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes, and devices and products used in intensive care units and hospital settings.
• Infusion Care (2022 revenue: $384m - 19%): disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as Parkinson's disease.

Further information about our business, markets, products and financial performance is included in our 2022 Annual Report and Accounts which can be viewedhere.

We have a clear vision - Pioneering trusted medical solutions to improve the lives we touch. This statement lies at the heart of everything we do. Along with our values, it guides how we run our business.

Our values are:

• Improve care: We are passionate about serving and supporting people with challenging
  medical conditions. We actively listen and respond to their needs: demonstrating deep empathy and using the insight we gain to develop and share innovative and trusted solutions.
• Deliver results: We consistently deliver excellent work, say what we do and do what we say. We focus on what matters to the people we serve, fulfilling our own roles while working in a team with shared goals. We keep things simple and strip out complexity wherever possible.
• Grow together: We help colleagues around us grow, develop and thrive, so we can all fulfil our potential and make Convatec a "destination employer". We respect what each of us contributes to Convatec: inspiring and supporting each other to excel, while sharing in our successes and learning from mistakes. We are candid, constructive and committed to collaboration with colleagues and partners.
• Own it: We take personal ownership of all our work: taking the initiative, innovating, taking smart risks and never settling for second best. We are bold but humble, manage ambiguity and move quickly to seize opportunities or adjust to new demands.
• Do what's right: We are honest and trustworthy, meeting our obligations and operating
  with the highest standards of integrity. We challenge what feels wrong: no matter what the issue or circumstances. We seek advice and input from others when in doubt. We embrace responsibility for our contribution to local communities and make a positive economic, environmental and social impact on society.

1. Following a strategic review of our Critical Care category, we withdrew from our hospital care business in 2022. As a result of this decision, we announced the closure of our factory in Belarus effective 31 May 2022.
2. This statement describes our organisational structure for the period under review. Since the end of that period, we have announced plans to integrate the
   operations of our Netherlands site to our current manufacturing site in Michalovce, Slovakia. This will result in the closure of our factory in the Netherlands effective Q1 2024.

2

Supply chain

Our supply chain includes third party operations in all parts of the world, including but not limited to China, Taiwan, UK, USA, Canada, Denmark, Slovakia, Italy, Switzerland, Sweden, France, Ireland, Spain, Poland, Turkey, Germany, The Netherlands, Mexico and Dominican Republic.

Our suppliers provide raw materials (e.g. chemicals, adhesives, films, PVC compounds, etc.), part finished products (e.g. moulded items), finished products, services (e.g. sterilisation) and research and development support. Our spend is concentrated towards a relatively small number of suppliers. For example:

• Ten suppliers represent approximately 80% of our contract manufacturing spend;
• Three suppliers represent approximately 70% of our logistics spend; while
• Our raw materials supply chain is more diverse, with 45 suppliers representing approximately 80% of our total raw material spend.

We are committed to working with our customers to address any concerns they have, including sharing best practices wherever requested. Like many medical device companies, our products are often sold by third parties, such as distributors.

Our human rights-related policies

We implement a number of policies and codes which are relevant to slavery, people trafficking, and human rights and ethical behaviour more broadly. We publish these policies and codes on our website, and they can be viewed here.

In 2022, we updated and republished our Human Rights and Labour Standards Policy(Policy), which applies to our own operations and employees, specifically addresses the United Nations Universal Declaration on Human Rights, the International Labour Organization's Declaration on Fundamental Principles and Rights at Work and the Ten Principles of the United Nations Global Compact. The Policy, which underpins the way we work with each other, with partners, and with customers and suppliers, was updated to include: explanation of our process for evaluating suppliers to ensure they align with our principles and practices; articulation of our approach to labour standards, including compliance with relevant laws and regulations in the countries in which we operate; and explanation of the Convatec Human Rights Committee and its role in monitoring implementation of the policy and leading any additional steps required. The Policy clearly states that "Convatec does not accept nor condone any form of modern slavery whether forced, compulsory or trafficked labour. Without limitation, Convatec does not engage sweatshop labour, convict labour or indentured labour under penal sanction."

The Policy is referenced in our Code of Ethics and Business Conduct (Code) which defines our core principles of ethical business practice and our standards for professional and personal behaviour. The Code includes sections on human rights, discrimination and harassment.

Every Convatec employee is required to report any actual or potential violation of either the Policy or the Code and communication channels are in place within the Group to facilitate and encourage such reporting, including an independently-managed confidential Compliance Helpline, described further below.

In many countries we conduct our business via third party distributors. We evaluate third party distributors prior to engagement (see further below) and require that our distributors comply with all applicable laws and regulations and our Global Third Party Compliance Manual(Manual). We also require that the Manual is cascaded with any parties in their value chain that are involved in Convatec business. We also undertake periodic audits of distributors to ensure compliance with the manual. Our Manual addresses issues of human rights and the prohibition of child labour, compulsory labour and human trafficking. Each third party that goes through our due diligence process will receive online Anti-Bribery and Anti-Corruption training that requires the third party to certify adherence to the Manual. All new Direct and Contract Manufacturing suppliers, and existing suppliers when their contracts are renewed, are also required to comply with the Manual.

Our cross-functional Human Rights Committee met three times in 2022. The Committee oversees Policy matters relating to human rights, as described further on page 5. The Committee includes senior representatives from our Supply Chain, Supplier Quality, Legal, Ethics and Compliance, Environmental, Social and Governance (ESG) and Human Resources teams, and sits as a working group with oversight from our Executive-level ESG Steering Committee. The Committee ensures

3

we regularly review and update our policies and codes which are relevant to slavery, people trafficking, and human rights and ethical behaviour.

Due diligence processes for slavery and human trafficking

Currently we use the following mechanisms to evaluate our suppliers and ensure their adherence to our values and ethics:

Third-party supplier assessment

To support our internal assessment of suppliers' compliance with the terms set out in our Manual, we operate a process managed by a third-party provider, EcoVadis. This process includes an evidence-based assessment which follows existing best practice and codes and is based on a comprehensive set of ethics, labour rights, health and safety, and environmental criteria which are closely aligned with the requirements set out in our Manual. Each assessment is tailored to fit the size, sector and geography of the individual supplier and covers issues including: health and safety, working conditions, child and forced labour, discrimination, energy and greenhouse gas emissions, water and waste management, use of chemicals, local pollution, corruption and bribery, information management, and the supplier's own supply chain assessment processes.

In 2022, we made good progress towards our ESG target of engaging with suppliers to utilise the EcoVadis platform, consistent with our target to ensure that 80% of Convatec's spend by Q4 2023 are asked to submit responses to this external ranking system. Utilising the EcoVadis platform helps identify improvement areas to focus on with our supply chain partners, including human rights matters. We take a proactive role in supporting key suppliers to take actions that can prompt feedback from their assessment score, as part of our overall approach to responsible supply chain stewardship. In 2022, these actions have helped contribute to a 6.5% increase in the average score of our rated partners. Further detail on the scoring can be viewed here.

As an example, led by our Global Procurement team, we worked with a key small and medium sized (SME) provider of roll stock (laminated film) that we use in our adhesive foam products. Following an assessment by EcoVadis, we reviewed the SME's action plan and supported them to make improvements. This included sharing good practice materials and policy examples to strengthen their focus on labour standards and human rights, environmental and ethical practices. This work resulted in the supplier meeting our expectations for a partner of this nature and them creating a revised employee handbook for their employees. Overall, this practice led to a 61% increase to their EcoVadis rating from 2021 to 2022, which as well as enhancing their relationship with Convatec, also strengthens their commercial position in the market.

In 2022, we included an assessment of potential new suppliers' ability to participate in the EcoVadis assessment process as part of our new sourcing process. This assessment is part of the Request for Information (RFI) and Request for Proposal (RFP) phases. In 2022, four out of seven RFI/RFP events requested details of EcoVadis status. The remaining three did not require assessment due to the type of service. Convatec requests the commitment of newly engaged suppliers to completing the EcoVadis assessment within a 6-month period from contract award.

We also evaluate our suppliers using a business review process that focuses on the quality of the product manufactured, the standard of documentation in place and other performance indicators. We use a third-party platform, Risk Methods, that feeds alerts and insights on labour standards and compliance issues directly to category managers. Suppliers are added to the platform in real time after selection. We also carry out cyclical quality audits assessing compliance with relevant regulations, as described below. All new direct material and contract manufacturing suppliers receive and are required to certify adherence to our Manual.

Certification - supplier agreements

We require our direct material and contract manufacturing suppliers to comply with the laws of the country in which they operate. To help ensure our suppliers respect and enforce our standards regarding anti-slavery and human trafficking, our template supplier agreement includes the following clause:

"Supplier represents, warrants and covenants that (i) it complies with all applicable laws on working hours and employment rights in the countries in which it operates; (ii) the evaluation and treatment of its employees and applicants for employment are free from discrimination and harassment, whether such discrimination or harassment is based on sex, age, race, colour, ancestry, religion, belief, disability, sexual orientation or marital status; (iii) the Products supplied under this Agreement shall be manufactured under conditions in compliance with the

4

principles set out in the International Labour Organization Eight Fundamental Conventions nos. 29, 87, 98, 100, 105, 111, 138 and 182 and in the United Nations Convention of the Rights of the Child Article 32; and (iv) no Products have been made in whole or in part by sweatshop labour, convict labour or indentured labour under penal sanction."

This clause is included in all new supplier agreements and is being phased into existing suppliers' agreements as and when their contracts are renewed.

As described in the previous section on our policies, each third party that goes through our due diligence process receives online Anti-Bribery and Anti-Corruption training that requires the third party to certify adherence to the Manual. Our Manual addresses issues of human rights and the prohibition of child labour, compulsory labour and human trafficking.

Audits

In accordance with the term of our Manual, we are entitled to perform various types of audit assessments to verify the current state of supplier compliance and undertake routine monitoring of the supplier's on-going compliance. If a supplier fails to comply with our Manual, we can either put in place a remediation plan or, in cases of severe non-compliance, refuse to pursue or terminate an existing relationship.

At the end of 2022, these processes did not reveal any issues that warrant an 'onsite' audit focused on trafficking and modern slavery to be conducted.

In 2022 we also contracted with SEDEX, with whom we will risk assess our third-party supply base to segment by level of potential human rights and labour standard risk factors. This will lead to a number of in-depth assessments both online via the SEDEX platform and on site to further ensure compliance. Further information can be viewed here.

Open communication and whistleblowing/speaking-up

For colleagues, we are committed to fostering a work environment where open, honest communications are the expectation, not the exception. We encourage our employees to approach their supervisor or other management in instances where they believe violations of policies or standards may have occurred, including in relation to trafficking or slavery issues. We also encourage them to ask if they require guidance about any of our policies and procedures.

We encourage all our stakeholders to 'speak up', in situations where either employees or any third- party prefers to place a report in confidence. We provide access to an independent Compliance Helpline, hosted by a third- party provider. This Compliance Helpline is available internally and on our website. Where there may be restrictions on confidential or anonymous employee reporting, employees are also directed to an internal confidential Convatec resource to help review and resolve any reports of concern. This would include issues relating to trafficking and slavery.

Risk assessment and management structures

The world is dynamic, and we face evolving variables that affect risk factors for modern slavery. In 2022, the Audit and Risk Committee of Convatec's Board of Directors adjusted Convatec's risk profile to reflect challenges from the macroeconomic environment, including global inflationary cost pressures, the ongoing supply chain and commercial impact of the Russian invasion into Ukraine and the continuing fallout from the COVID-19 pandemic. Having considered severe but plausible scenarios that took these factors into consideration (either explicitly or implicitly) , the Committee concluded that the Board should have a reasonable expectation that the Group will be able to continue to operate during the three-year viability period to 2025 (inclusive).

As mentioned above, our cross-functional Human Rights Committee includes representatives from our Supply Chain, Supplier Quality, Legal, Ethics and Compliance, ESG and Human Resources teams. Its scope of work includes:

• Overseeing audits from business partners/third party adherence to our global human rights policies, standards and practices
• Review of the annual Modern Slavery Act Statement to support disclosure arrangements
• Follow any changes in stakeholder expectations and sharing best practices on Human Rights-related topics to further embed these across the Group and its operations
• Commissioning additional activities in furtherance of our global human rights policies, standards and practices that further embed these in our business operations such as education and training of employees and third parties.

5